Lyra Therapeutics, Inc.: 1 tracked 2026 layoff event(s), 0 workers counted, highest AI score 7.
AI score 7 (80% interval 5–8) · evidence grade D · US · Instruments / Medical Devices
Stated reason: On January 9, 2026, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) approved a plan to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis, and to implement a cost reduction plan that includes a workforce reduction impacting substantially all of the Company’s remaining employees, effective January 12, 2026, and other cost-saving ac…
Why 7: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5, role AI exposure +0.2
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.761, industry exposure 0.712, AI investment 0.0, contrary 0.0 · named roles: Computer and Information Systems Managers, General and Operations Managers
Headcount basis: not disclosed
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
